Should You Ditch GlaxoSmithKline plc And Buy Vectura Group PLC And SkyePharma PLC?

Are these 2 pharmaceutical stocks better buys that GlaxoSmithKline plc (LON: GSK)? Check out Vectura Group PLC (LON: VEC) and SkyePharma PLC (LON: SKP).

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

With the stock market having been akin to a rollercoaster ride so far in 2016, many investors are understandably seeking out defensive stocks. This makes sense because a volatile portfolio is never much fun and can lead to a great deal of worry and the potential for sleepless nights.

One stock that offers defensive characteristics is GlaxoSmithKline (LSE: GSK). Part of the reason for this is the fact that its profitability is less positively correlated to the performance of the global economy than is the case for most of its FTSE 100 peers. In other words, GlaxoSmithKline depends less on GDP growth and more on a strong drugs pipeline for its bottom-line growth. As such, even if there’s further volatility in share prices, GlaxoSmithKline could continue to outperform the FTSE 100, as it has done since the turn of the year, by over 5%.

In addition, GlaxoSmithKline also pays a superb dividend. It currently yields 5.8% and although dividends are due to flatline over the next couple of years as the company implements a major restructuring programme, its shareholder payouts remain relatively high and consistent. During a period of uncertainty this is a superb ally for nervous investors.

As well as defensive attributes, GlaxoSmithKline also has a strong pipeline of new drugs that have the potential to rapidly increase its sales and profit over the medium-to-long term. In fact, GlaxoSmithKline’s portfolio is one of the most diversified in the business and it has real potential to generate multiple blockbuster drugs, with its ViiV Health Care subsidiary being of key importance to the company’s long-term growth. And with its bottom line due to be positively impacted by cost cuts, GlaxoSmithKline seems to be an excellent buy for the long term.

What’s the alternative?

Of course, it’s not the only stock in the pharmaceutical sector that could be worth adding to your portfolio. In fact, there are a number of companies that offer tremendous forecast growth rates and yet trade on highly appealing valuations.

For example, airways diseases specialist Vectura (LSE: VEC) is forecast to increase its bottom line by 116% in the next financial year following what’s expected to be a profitable year in 2016. And with its shares trading on a price-to-earnings (P/E) ratio of 53, this equates to a price-to-earnings growth (PEG) ratio of only 0.5. This indicates that they could deliver improved performance following their fall of 8% in the last six months.

Similarly, drug delivery specialist SkyePharma (LSE: SKP) is due to post a rise in its bottom line of 51% in 2016. When combined with its P/E ratio of 25.6, this equates to a PEG ratio of only 0.5 and indicates that there’s considerable upside potential. As with Vectura, SkyePharma pays no dividend and isn’t expected to commence shareholder payouts this year. In addition, the two companies are much smaller than GlaxoSmithKline and arguably offer less defensive characteristics or stability, but do have greater growth potential.

As such, a mix of all three stocks seems to be a sound move, although for investors who are only able to buy one of the three companies, GlaxoSmithKline appears to have the perfect mix of growth, income and defensive qualities.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Peter Stephens owns shares of GlaxoSmithKline. The Motley Fool UK has recommended GlaxoSmithKline. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Close up of manual worker's equipment at construction site without people.
Investing Articles

Investing £14,708 in this FTSE 100 stock could earn me £1,000 per year in passive income

Is a CMA investigation into anticompetitive practices the cloud cover Stephen Wright needs to start buying shares in a FTSE…

Read more »

Investing Articles

Despite rising 152% in a year, is Rolls-Royce’s share price still a bargain?

While Rolls-Royce’s share price has shot up recently, it still looks very undervalued against its peers, and the business looks…

Read more »

Investing Articles

Could Nvidia stock be a bargain in plain sight?

Nvidia stock has surged 252% over the past 12 months, but that doesn't mean it's expensive. In fact, it may…

Read more »

Investing Articles

Here’s why I think the Vodafone share price should be 110% higher

Reflecting on speculation, our writer believes there’s a case to be made for the Vodafone share price being more than…

Read more »

A pastel colored growing graph with rising rocket.
Investing Articles

Is this dividend star also the best bargain in the FTSE 100?

This FTSE 100 stock pays a whopping 8%+ yield, looks very undervalued against its peers, and is set for stellar…

Read more »

Investing Articles

2 FTSE 100 stocks. One sublime, the other ridiculous

Our writer doesn’t understand the appeal of Ocado. But looking at the grocer’s latest results makes him see the attraction…

Read more »

Portrait of elderly man wearing white denim shirt and glasses looking up with hand on chin. Thoughtful senior entrepreneur, studio shot against grey background.
Investing Articles

Down 18% in a year, what’s next for the Greatland Gold (GGP) share price?

The Greatland Gold share price has disappointed over the past 12 months. Our writer asks whether the company’s latest update…

Read more »

Investor looking at stock graph on a tablet with their finger hovering over the Buy button
Investing Articles

With 30% annual returns for a decade, I’m buying this for my Stocks & Shares ISA

Oliver Rodzianko has been looking for a new investment for his Stocks and Shares ISA. Here's one he's decided is…

Read more »